BC Week In Review | May 2, 2011
Clinical News

Bone Marrow Aspiration Concentrate: Phase I started

Harvest began the open-label, international Phase I REVIVE-1 trial to evaluate a coronary sinus infusion of 60 mL BMAC in about 60 patients. Harvest Technologies Corp. , Plymouth, Mass.   Product: Bone Marrow Aspiration Concentrate (BMAC)...
BC Week In Review | Mar 28, 2011
Clinical News

Bone Marrow Aspiration Concentrate: Pivotal trial start

Next quarter, Harvest will begin a double-blind, placebo-controlled, U.S. pivotal trial in 210 patients to evaluate 40 mL BMAC injected into ischemic tissues of the lower limb. Harvest Technologies Corp. , Plymouth, Mass.   Product: Bone...
BC Week In Review | Dec 7, 2009
Clinical News

BMAC: Phase I/II data

An open-label, Indian Phase I/II trial in 60 patients showed that 90% of patients avoided leg amputation at 12 weeks after receiving BMAC. BMAC also led to a significant reduction in pain perception, and significant...
BC Week In Review | Nov 16, 2009
Clinical News

BMAC: Completed feasibility study enrollment

Harvest completed enrollment of 48 patients in a U.S. and Indian feasibility study evaluating its BMAC system. Harvest Technologies Corp. , Plymouth, Mass.   Product: BMAC, bone marrow nucleated cells   Business: Cardiovascular   Molecular target:...
BC Week In Review | Apr 13, 2009
Clinical News

BMAC: Interim Phase I/II data

Interim data from the first 30 patients in an open-label, Indian Phase I/II trial showed that 88% of patients avoided leg amputation at 12 weeks after receiving nucleated BMAC. Patients also reported significantly improved quality...
Items per page:
1 - 5 of 5